MedTrace Logo

An Extension of CTN 31GB0607 to Evaluate Long Term Safety of NASHA Treatment in the Breast

NCT01609400 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2022-08-25

No results posted yet for this study

Summary

The study evaluates degradation of NASHA in breast 4 and 6 years post treatment, long term safety and evaluation if a satisfactory breast cancer screening can be performed in subjects treated with NASHA-gel in breast. An independent evaluation of the aesthetic changes is also performed.

Conditions

  • Breast Enhancement

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Per Hedén, M.D. · Akademikliniken, Stockholm, Sweden

  • Michael Olenius, M.D. · Proforma Clinic AB, Stockholm, Sweden

Eligibility

Min Age
25 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-08-31
Completion
2013-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01609400 on ClinicalTrials.gov